Clinical Trials Logo
  1. Home
  2. Epilepsy, Partial
  3. NCT00152451

Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures

Epilepsy, Partial Clinical Trial

Official title:
An Open-label, Exploratory, Multicenter, Dose-escalation Study Examining the Efficacy, Safety and Tolerability of Ucb 44212 Used at Doses of 10 mg, 20 mg, 40 mg and 80 mg b.i.d. (Total Daily Dose of 20 to 160 mg) in Adult Subjects (18-65 Years) With Refractory Epilepsy Suffering From Partial Onset Seizures (Whether or Not Secondarily Generalized) and Treated With 1, 2 or 3 Approved Antiepileptic Drugs

Clinical Trial Summary

This trial will evaluate the efficacy and safety of ucb 44212 as add on therapy in subjects with focal epilepsy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00152451
Study type Interventional
Source UCB Pharma
Contact
Status Completed
Phase Phase 2
Start date May 19, 2005
Completion date May 3, 2006
View Details
See also
  Status Clinical Trial Phase
Completed NCT00105040 - A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures Phase 2
Completed NCT00160615 - Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method Phase 3
Completed NCT00152516 - Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures Phase 3
Completed NCT00113165 - Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures Phase 3
Completed NCT00175890 - A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures. Phase 3
Withdrawn NCT01691872 - Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects Phase 1
Completed NCT00160654 - Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy Phase 4
Terminated NCT01545518 - IVIG Treatment for Refractory Immune-Related Adult Epilepsy Phase 2
Completed NCT00141414 - To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy. Phase 2
Completed NCT01332539 - An Observational Study to Assess the Burden of Drug-resistant Partial Epilepsy in Italy N/A
Completed NCT00355082 - Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy Phase 3
Withdrawn NCT02220972 - To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures Phase 4
Completed NCT00160628 - Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy Phase 3
Completed NCT00245713 - Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy. Phase 4
Terminated NCT01375374 - Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide Phase 3
Completed NCT00152373 - Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POS Phase 3
Completed NCT00150709 - A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy Phase 3
Completed NCT00643500 - Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy Phase 4
Completed NCT00152503 - Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam Phase 2
Terminated NCT01891890 - Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE) Phase 3